ID   GRIA3_HUMAN             Reviewed;         894 AA.
AC   P42263; D3DTF1; Q4VXD5; Q4VXD6; Q9HDA0; Q9HDA1; Q9HDA2; Q9P0H1;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 2.
DT   28-JUN-2023, entry version 214.
DE   RecName: Full=Glutamate receptor 3;
DE            Short=GluR-3;
DE   AltName: Full=AMPA-selective glutamate receptor 3;
DE   AltName: Full=GluR-C;
DE   AltName: Full=GluR-K3;
DE   AltName: Full=Glutamate receptor ionotropic, AMPA 3;
DE            Short=GluA3;
DE   Flags: Precursor;
GN   Name=GRIA3; Synonyms=GLUR3, GLURC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS FLIP AND FLOP), AND VARIANT LEU-525.
RC   TISSUE=Hippocampus;
RX   PubMed=7918660; DOI=10.1016/0167-4781(94)90090-6;
RA   Rampersad V., Elliott C.E., Nutt S.L., Foldes R.L., Kamboj R.K.;
RT   "Human glutamate receptor hGluR3 flip and flop isoforms: cloning and
RT   sequencing of the cDNAs and primary structure of the proteins.";
RL   Biochim. Biophys. Acta 1219:563-566(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   McLaughlin D.P., Kerwin R.W.;
RL   Submitted (OCT-1994) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-525.
RX   PubMed=10644433; DOI=10.1006/geno.1999.6032;
RA   Gecz J., Barnett S., Liu J., Hollway G., Donnelly A., Eyre H.,
RA   Eshkevari H.S., Baltazar R., Grunn A., Nagaraja R., Gilliam C.,
RA   Peltonen L., Sutherland G.R., Baron M., Mulley J.C.;
RT   "Characterization of the human glutamate receptor subunit 3 gene (GRIA3), a
RT   candidate for bipolar disorder and nonspecific X-linked mental
RT   retardation.";
RL   Genomics 62:356-368(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-525.
RX   PubMed=10602120;
RX   DOI=10.1002/(sici)1096-8628(20000103)90:1<69::aid-ajmg12>3.3.co;2-n;
RA   Amir R., Dahle E.J., Toriolo D., Zoghbi H.Y.;
RT   "Candidate gene analysis in Rett syndrome and the identification of 21 SNPs
RT   in Xq.";
RL   Am. J. Med. Genet. 90:69-71(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   FUNCTION.
RX   PubMed=21172611; DOI=10.1016/j.neuron.2010.11.026;
RA   Kato A.S., Gill M.B., Ho M.T., Yu H., Tu Y., Siuda E.R., Wang H.,
RA   Qian Y.W., Nisenbaum E.S., Tomita S., Bredt D.S.;
RT   "Hippocampal AMPA receptor gating controlled by both TARP and cornichon
RT   proteins.";
RL   Neuron 68:1082-1096(2010).
RN   [8]
RP   VARIANTS MRXSW GLN-450; SER-631; THR-706 AND ARG-833, AND CHARACTERIZATION
RP   OF VARIANTS MRXSW SER-631; THR-706 AND ARG-833.
RX   PubMed=17989220; DOI=10.1073/pnas.0708699104;
RA   Wu Y., Arai A.C., Rumbaugh G., Srivastava A.K., Turner G., Hayashi T.,
RA   Suzuki E., Jiang Y., Zhang L., Rodriguez J., Boyle J., Tarpey P.,
RA   Raymond F.L., Nevelsteen J., Froyen G., Stratton M., Futreal A., Gecz J.,
RA   Stevenson R., Schwartz C.E., Valle D., Huganir R.L., Wang T.;
RT   "Mutations in ionotropic AMPA receptor 3 alter channel properties and are
RT   associated with moderate cognitive impairment in humans.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:18163-18168(2007).
RN   [9]
RP   VARIANT LYS-224.
RX   PubMed=30165711; DOI=10.1055/s-0038-1668141;
RA   Fazeli W., Becker K., Herkenrath P., Duechting C., Koerber F., Landgraf P.,
RA   Nuernberg P., Altmueller J., Thiele H., Koy A., Liebau M.C., Simon T.,
RA   Doetsch J., Cirak S.;
RT   "Dominant SCN2A Mutation Causes Familial Episodic Ataxia and Impairment of
RT   Speech Development.";
RL   Neuropediatrics 49:379-384(2018).
CC   -!- FUNCTION: Receptor for glutamate that functions as ligand-gated ion
CC       channel in the central nervous system and plays an important role in
CC       excitatory synaptic transmission. L-glutamate acts as an excitatory
CC       neurotransmitter at many synapses in the central nervous system.
CC       Binding of the excitatory neurotransmitter L-glutamate induces a
CC       conformation change, leading to the opening of the cation channel, and
CC       thereby converts the chemical signal to an electrical impulse. The
CC       receptor then desensitizes rapidly and enters a transient inactive
CC       state, characterized by the presence of bound agonist. In the presence
CC       of CACNG4 or CACNG7 or CACNG8, shows resensitization which is
CC       characterized by a delayed accumulation of current flux upon continued
CC       application of glutamate. {ECO:0000269|PubMed:21172611}.
CC   -!- SUBUNIT: Homotetramer or heterotetramer of pore-forming glutamate
CC       receptor subunits. Tetramers may be formed by the dimerization of
CC       dimers. Interacts with PRKCABP, GRIP1 and GRIP2 (By similarity). Found
CC       in a complex with GRIA1, GRIA2, GRIA4, CNIH2, CNIH3, CACNG2, CACNG3,
CC       CACNG4, CACNG5, CACNG7 and CACNG8. Interacts with CACNG5 (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Postsynaptic cell membrane; Multi-pass membrane protein.
CC       Note=Interaction with CNIH2 and CNIH3 promotes cell surface expression.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Flop;
CC         IsoId=P42263-1; Sequence=Displayed;
CC       Name=Flip;
CC         IsoId=P42263-2; Sequence=VSP_053351;
CC   -!- DOMAIN: The M4 transmembrane segment mediates tetramerization and is
CC       required for cell surface expression. {ECO:0000250}.
CC   -!- PTM: Palmitoylated. Depalmitoylated upon glutamate stimulation. Cys-621
CC       palmitoylation leads to Golgi retention and decreased cell surface
CC       expression. In contrast, Cys-847 palmitoylation does not affect cell
CC       surface expression but regulates stimulation-dependent endocytosis (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Intellectual developmental disorder, X-linked, syndromic, Wu
CC       type (MRXSW) [MIM:300699]: A disorder characterized by significantly
CC       below average general intellectual functioning associated with
CC       impairments in adaptive behavior and manifested during the
CC       developmental period. MRXSW patients have moderate intellectual
CC       disability, and additional variable features such as macrocephaly,
CC       seizures, myoclonic jerks, autistic behavior, asthenic body habitus,
CC       distal muscle weakness and hyporeflexia. {ECO:0000269|PubMed:17989220}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: The postsynaptic actions of Glu are mediated by a
CC       variety of receptors that are named according to their selective
CC       agonists. This receptor binds AMPA (quisqualate) > glutamate > kainate.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel (TC 1.A.10.1)
CC       family. GRIA3 subfamily. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-7 is the initiator.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U10302; AAA67923.1; -; mRNA.
DR   EMBL; U10301; AAA67922.1; -; mRNA.
DR   EMBL; X82068; CAA57567.1; -; mRNA.
DR   EMBL; AF159277; AAF61847.1; -; Genomic_DNA.
DR   EMBL; AF159262; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159263; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159264; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159265; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159266; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159267; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159268; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159269; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159270; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159271; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159272; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159273; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159274; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF159275; AAF61847.1; JOINED; Genomic_DNA.
DR   EMBL; AF166365; AAF97857.1; -; Genomic_DNA.
DR   EMBL; AF166362; AAF97857.1; JOINED; Genomic_DNA.
DR   EMBL; AF166363; AAF97857.1; JOINED; Genomic_DNA.
DR   EMBL; AF166364; AAF97857.1; JOINED; Genomic_DNA.
DR   EMBL; AF167332; AAF97858.1; -; Genomic_DNA.
DR   EMBL; AF166366; AAF97858.1; JOINED; Genomic_DNA.
DR   EMBL; AF166367; AAF97858.1; JOINED; Genomic_DNA.
DR   EMBL; AF166368; AAF97858.1; JOINED; Genomic_DNA.
DR   EMBL; AF166369; AAF97858.1; JOINED; Genomic_DNA.
DR   EMBL; AF166370; AAF97858.1; JOINED; Genomic_DNA.
DR   EMBL; AF166371; AAF97858.1; JOINED; Genomic_DNA.
DR   EMBL; AF166372; AAF97858.1; JOINED; Genomic_DNA.
DR   EMBL; AF166373; AAF97858.1; JOINED; Genomic_DNA.
DR   EMBL; AF166375; AAF97858.1; JOINED; Genomic_DNA.
DR   EMBL; AF167332; AAF97859.1; -; Genomic_DNA.
DR   EMBL; AF166366; AAF97859.1; JOINED; Genomic_DNA.
DR   EMBL; AF166367; AAF97859.1; JOINED; Genomic_DNA.
DR   EMBL; AF166368; AAF97859.1; JOINED; Genomic_DNA.
DR   EMBL; AF166369; AAF97859.1; JOINED; Genomic_DNA.
DR   EMBL; AF166370; AAF97859.1; JOINED; Genomic_DNA.
DR   EMBL; AF166371; AAF97859.1; JOINED; Genomic_DNA.
DR   EMBL; AF166372; AAF97859.1; JOINED; Genomic_DNA.
DR   EMBL; AF166373; AAF97859.1; JOINED; Genomic_DNA.
DR   EMBL; AF166374; AAF97859.1; JOINED; Genomic_DNA.
DR   EMBL; AL356213; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590139; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z83848; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z82899; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL035426; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471107; EAX11865.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11867.1; -; Genomic_DNA.
DR   CCDS; CCDS14604.1; -. [P42263-1]
DR   CCDS; CCDS14605.1; -. [P42263-2]
DR   PIR; S49460; S49460.
DR   PIR; S50128; S50128.
DR   PIR; S53696; S53696.
DR   RefSeq; NP_000819.3; NM_000828.4. [P42263-1]
DR   RefSeq; NP_015564.4; NM_007325.4. [P42263-2]
DR   AlphaFoldDB; P42263; -.
DR   SMR; P42263; -.
DR   BioGRID; 109149; 27.
DR   DIP; DIP-46195N; -.
DR   IntAct; P42263; 17.
DR   MINT; P42263; -.
DR   STRING; 9606.ENSP00000481554; -.
DR   BindingDB; P42263; -.
DR   ChEMBL; CHEMBL3595; -.
DR   DrugBank; DB04599; Aniracetam.
DR   DrugBank; DB00237; Butabarbital.
DR   DrugBank; DB05047; CX-717.
DR   DrugBank; DB00898; Ethanol.
DR   DrugBank; DB13146; Fluciclovine (18F).
DR   DrugBank; DB00142; Glutamic acid.
DR   DrugBank; DB14509; Lithium carbonate.
DR   DrugBank; DB01356; Lithium cation.
DR   DrugBank; DB14507; Lithium citrate.
DR   DrugBank; DB14508; Lithium succinate.
DR   DrugBank; DB04982; Talampanel.
DR   DrugCentral; P42263; -.
DR   GuidetoPHARMACOLOGY; 446; -.
DR   TCDB; 1.A.10.1.4; the glutamate-gated ion channel (gic) family of neurotransmitter receptors.
DR   GlyCosmos; P42263; 5 sites, No reported glycans.
DR   GlyGen; P42263; 5 sites.
DR   iPTMnet; P42263; -.
DR   PhosphoSitePlus; P42263; -.
DR   SwissPalm; P42263; -.
DR   BioMuta; GRIA3; -.
DR   DMDM; 77416864; -.
DR   EPD; P42263; -.
DR   MassIVE; P42263; -.
DR   PaxDb; P42263; -.
DR   PeptideAtlas; P42263; -.
DR   ProteomicsDB; 55501; -. [P42263-1]
DR   ProteomicsDB; 55502; -. [P42263-2]
DR   Antibodypedia; 29962; 375 antibodies from 30 providers.
DR   DNASU; 2892; -.
DR   Ensembl; ENST00000620443.2; ENSP00000478489.1; ENSG00000125675.20. [P42263-2]
DR   Ensembl; ENST00000622768.5; ENSP00000481554.1; ENSG00000125675.20. [P42263-1]
DR   GeneID; 2892; -.
DR   KEGG; hsa:2892; -.
DR   MANE-Select; ENST00000620443.2; ENSP00000478489.1; NM_007325.5; NP_015564.5. [P42263-2]
DR   UCSC; uc033etl.2; human. [P42263-1]
DR   AGR; HGNC:4573; -.
DR   CTD; 2892; -.
DR   DisGeNET; 2892; -.
DR   GeneCards; GRIA3; -.
DR   HGNC; HGNC:4573; GRIA3.
DR   HPA; ENSG00000125675; Tissue enhanced (brain, retina).
DR   MalaCards; GRIA3; -.
DR   MIM; 300699; phenotype.
DR   MIM; 305915; gene.
DR   neXtProt; NX_P42263; -.
DR   OpenTargets; ENSG00000125675; -.
DR   Orphanet; 364028; X-linked intellectual disability due to GRIA3 mutations.
DR   PharmGKB; PA28968; -.
DR   VEuPathDB; HostDB:ENSG00000125675; -.
DR   eggNOG; KOG1054; Eukaryota.
DR   GeneTree; ENSGT00940000156123; -.
DR   HOGENOM; CLU_007257_1_2_1; -.
DR   InParanoid; P42263; -.
DR   OMA; WHRTIAT; -.
DR   OrthoDB; 511851at2759; -.
DR   PhylomeDB; P42263; -.
DR   TreeFam; TF315232; -.
DR   PathwayCommons; P42263; -.
DR   Reactome; R-HSA-399710; Activation of AMPA receptors.
DR   Reactome; R-HSA-399719; Trafficking of AMPA receptors.
DR   Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; R-HSA-438066; Unblocking of NMDA receptors, glutamate binding and activation.
DR   Reactome; R-HSA-8849932; Synaptic adhesion-like molecules.
DR   SignaLink; P42263; -.
DR   SIGNOR; P42263; -.
DR   BioGRID-ORCS; 2892; 9 hits in 774 CRISPR screens.
DR   ChiTaRS; GRIA3; human.
DR   GeneWiki; GRIA3; -.
DR   GenomeRNAi; 2892; -.
DR   Pharos; P42263; Tclin.
DR   PRO; PR:P42263; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P42263; protein.
DR   Bgee; ENSG00000125675; Expressed in Brodmann (1909) area 23 and 142 other tissues.
DR   ExpressionAtlas; P42263; baseline and differential.
DR   Genevisible; P42263; HS.
DR   GO; GO:0032281; C:AMPA glutamate receptor complex; ISS:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IBA:GO_Central.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0098688; C:parallel fiber to Purkinje cell synapse; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0098839; C:postsynaptic density membrane; IBA:GO_Central.
DR   GO; GO:0004971; F:AMPA glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0001540; F:amyloid-beta binding; ISS:ARUK-UCL.
DR   GO; GO:0099507; F:ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential; IDA:SynGO.
DR   GO; GO:1904315; F:transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential; IBA:GO_Central.
DR   GO; GO:0007215; P:glutamate receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IBA:GO_Central.
DR   CDD; cd06387; PBP1_iGluR_AMPA_GluR3; 1.
DR   CDD; cd13715; PBP2_iGluR_AMPA; 1.
DR   Gene3D; 1.10.287.70; -; 2.
DR   Gene3D; 3.40.50.2300; -; 2.
DR   Gene3D; 3.40.190.10; Periplasmic binding protein-like II; 2.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_Glu_rcpt_met.
DR   InterPro; IPR015683; Ionotropic_Glu_rcpt.
DR   InterPro; IPR001320; Iontro_rcpt_C.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   PANTHER; PTHR18966:SF151; GLUTAMATE RECEPTOR 3; 1.
DR   PANTHER; PTHR18966; IONOTROPIC GLUTAMATE RECEPTOR; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; Periplasmic binding protein-like I; 1.
DR   SUPFAM; SSF53850; Periplasmic binding protein-like II; 1.
DR   SUPFAM; SSF81324; Voltage-gated potassium channels; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Disease variant; Disulfide bond;
KW   Glycoprotein; Intellectual disability; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Signal; Synapse;
KW   Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL          1..28
FT                   /evidence="ECO:0000255"
FT   CHAIN           29..894
FT                   /note="Glutamate receptor 3"
FT                   /id="PRO_0000011536"
FT   TOPO_DOM        29..552
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        553..573
FT                   /note="Helical"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        574..602
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   INTRAMEM        603..618
FT                   /note="Helical; Pore-forming"
FT                   /evidence="ECO:0000250"
FT   INTRAMEM        619..621
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        622..627
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        628..648
FT                   /note="Helical"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        649..823
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        824..844
FT                   /note="Helical; Name=M4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        845..894
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   BINDING         480
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   BINDING         508..510
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   BINDING         515
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   BINDING         686..687
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   BINDING         737
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         877
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2W9"
FT   MOD_RES         887
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2W9"
FT   LIPID           621
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   LIPID           847
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        63
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        266
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        380
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        415
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        422
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        91..340
FT                   /evidence="ECO:0000250"
FT   DISULFID        750..805
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         776..811
FT                   /note="NAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGD -> TPVNLAVLKLSE
FT                   QGILDKLKNKWWYDKGECGAKDSG (in isoform Flip)"
FT                   /evidence="ECO:0000303|PubMed:7918660"
FT                   /id="VSP_053351"
FT   VARIANT         224
FT                   /note="E -> K (found in patients with familial episodic
FT                   ataxia and impairment of speech development; unknown
FT                   pathological significance; dbSNP:rs757586471)"
FT                   /evidence="ECO:0000269|PubMed:30165711"
FT                   /id="VAR_081437"
FT   VARIANT         450
FT                   /note="R -> Q (in MRXSW; dbSNP:rs368568228)"
FT                   /evidence="ECO:0000269|PubMed:17989220"
FT                   /id="VAR_043484"
FT   VARIANT         525
FT                   /note="F -> L (in dbSNP:rs1052538)"
FT                   /evidence="ECO:0000269|PubMed:10602120,
FT                   ECO:0000269|PubMed:10644433, ECO:0000269|PubMed:7918660"
FT                   /id="VAR_023579"
FT   VARIANT         631
FT                   /note="R -> S (in MRXSW; homomers have minimal or no
FT                   current; heteromers have altered desensitization kinetics;
FT                   dbSNP:rs137852351)"
FT                   /evidence="ECO:0000269|PubMed:17989220"
FT                   /id="VAR_043485"
FT   VARIANT         706
FT                   /note="M -> T (in MRXSW; homomers have minimal or no
FT                   current; heteromers have altered desensitization kinetics;
FT                   dbSNP:rs137852352)"
FT                   /evidence="ECO:0000269|PubMed:17989220"
FT                   /id="VAR_043486"
FT   VARIANT         833
FT                   /note="G -> R (in MRXSW; reduced receptor expression
FT                   possibly due to rapid degradation; dbSNP:rs137852350)"
FT                   /evidence="ECO:0000269|PubMed:17989220"
FT                   /id="VAR_043487"
FT   CONFLICT        195
FT                   /note="N -> H (in Ref. 3; AAF61847)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        775
FT                   /note="R -> G (in Ref. 1; AAA67922/AAA67923, 2; CAA57567
FT                   and 3; AAF61847)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   894 AA;  101157 MW;  178589A870E0D102 CRC64;
     MARQKKMGQS VLRAVFFLVL GLLGHSHGGF PNTISIGGLF MRNTVQEHSA FRFAVQLYNT
     NQNTTEKPFH LNYHVDHLDS SNSFSVTNAF CSQFSRGVYA IFGFYDQMSM NTLTSFCGAL
     HTSFVTPSFP TDADVQFVIQ MRPALKGAIL SLLGHYKWEK FVYLYDTERG FSILQAIMEA
     AVQNNWQVTA RSVGNIKDVQ EFRRIIEEMD RRQEKRYLID CEVERINTIL EQVVILGKHS
     RGYHYMLANL GFTDILLERV MHGGANITGF QIVNNENPMV QQFIQRWVRL DEREFPEAKN
     APLKYTSALT HDAILVIAEA FRYLRRQRVD VSRRGSAGDC LANPAVPWSQ GIDIERALKM
     VQVQGMTGNI QFDTYGRRTN YTIDVYEMKV SGSRKAGYWN EYERFVPFSD QQISNDSASS
     ENRTIVVTTI LESPYVMYKK NHEQLEGNER YEGYCVDLAY EIAKHVRIKY KLSIVGDGKY
     GARDPETKIW NGMVGELVYG RADIAVAPLT ITLVREEVID FSKPFMSLGI SIMIKKPQKS
     KPGVFSFLDP LAYEIWMCIV FAYIGVSVVL FLVSRFSPYE WHLEDNNEEP RDPQSPPDPP
     NEFGIFNSLW FSLGAFMQQG CDISPRSLSG RIVGGVWWFF TLIIISSYTA NLAAFLTVER
     MVSPIESAED LAKQTEIAYG TLDSGSTKEF FRRSKIAVYE KMWSYMKSAE PSVFTKTTAD
     GVARVRKSKG KFAFLLESTM NEYIEQRKPC DTMKVGGNLD SKGYGVATPK GSALRNAVNL
     AVLKLNEQGL LDKLKNKWWY DKGECGSGGG DSKDKTSALS LSNVAGVFYI LVGGLGLAMM
     VALIEFCYKS RAESKRMKLT KNTQNFKPAP ATNTQNYATY REGYNVYGTE SVKI
//
